AOCI at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's AOCI?
- Jazz Pharmaceuticals (JAZZ) reported AOCI of -$651M in Q1 2026.
- How has Jazz Pharmaceuticals's AOCI changed year-over-year?
- Jazz Pharmaceuticals's AOCI increased by 17.1% year-over-year, from -$785.61M to -$651M.
- What is the long-term trend for Jazz Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's AOCI has grown at a 33.4% compound annual growth rate (CAGR), from -$134.35M to -$568.6M.
- What does AOCI mean?
- A bucket for cumulative gains and losses that bypass the income statement, such as currency fluctuations.
- How do you interpret AOCI?
- Large swings can indicate exposure to foreign exchange risk or volatility in the fair value of investment portfolios.
- How does AOCI compare across companies?
- Standard across all firms; highly dependent on global operations and hedging strategies.